Novo Nordisk Price Cut Expands Medicare Access
Novo Nordisk price cut lowers cash costs and ties GLP-1 pricing to a 2026 Medicare pilot, reshaping reimbursement and access for weight-loss drugs.
KEY TAKEAWAYS
- Novo Nordisk cut Wegovy and Ozempic cash prices to $349 per month on Nov. 17, 2025.
- Medicare pilot begins April 2026 with negotiated price $245 per month and a $50 beneficiary copay.
- TrumpRx launches January 2026 to sell GLP-1s at $350 per month, aligning cash and Medicare pricing.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk (NVO) cut prices on Nov. 17, 2025, lowering consumer costs for Wegovy and Ozempic as part of a Trump administration agreement that also establishes Medicare coverage for GLP-1 drugs starting in 2026.
Cash Prices and TrumpRx Platform
Novo Nordisk reduced the cash price for Wegovy and Ozempic to $349 per month for existing patients paying out of pocket, shifting a key retail price point away from insurer negotiations. The company introduced an offer for new cash customers: $199 per month for the first two months on the lowest doses.
The TrumpRx platform will launch in January 2026, selling GLP-1 drugs directly to consumers at $350 per month. The platform aims to align cash prices with Medicare levels over two years. Oral GLP-1 therapies, if approved by the FDA, will also be eligible for TrumpRx pricing.
Medicare and Medicaid Coverage Expansion
The Centers for Medicare & Medicaid Services (CMS) will start a pilot program in April 2026, which will become mandatory in 2027. Under this program, Medicare will pay $245 per month, and beneficiaries will have a $50 monthly copay. The Inflation Reduction Act’s price-negotiation rules, effective in 2027, could further reduce costs.
Medicaid programs will access the same negotiated prices as Medicare, while group health plans remain unaffected by the federal agreement.
Medicare coverage eligibility is limited to patients with severe obesity, defined as a body-mass index above 35, or overweight beneficiaries with qualifying comorbidities such as prediabetes, cardiovascular disease, advanced kidney disease, heart failure, and uncontrolled hypertension. Officials estimate about 10% of Medicare enrollees meet these criteria.
Novo Nordisk and Eli Lilly reached this agreement with the Trump administration under the Most Favored Nation drug-pricing initiative, linking their pricing to a federal framework and centralizing lower prices for GLP-1 manufacturers.
Following FDA resolution of shortages in early 2025, compounded versions of semaglutide were discontinued, leaving only brand-name options as the market adjusts to new pricing and distribution channels.
This package of price reductions, direct-to-consumer sales, and a CMS pilot aims to improve affordability and access for older adults and disabled beneficiaries while setting a timeline for federal reimbursement and future price negotiations under existing drug-pricing laws.
